glp 1 drugs heart failure The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Potential Mechanisms of the Protective
Description
Using RT-PCR analysis, the expression of TRPA1 mRNA in STC-1 cells was confirmed (Fig
doi: 10.1136/bmjopen-2015-009579
Another study has reported that treatment of the DPP-4 inhibitor vildagliptin (10 mg/kg) in STZ-induced diabetic rats suppresses plasma TNF- concentrations and inhibits nitric oxide concentrations in the serum (Akarte et al., 2012)
Additionally, GLP-1 RAs demonstrate promising effects on metabolic liver disease, reducing steatohepatitis and fibrosis progression
I am not given up my *affiliated* PCP over this, which is why I am trying the endocrinology route
& Min, T
